Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $53.67.
Several equities research analysts have recently issued reports on IDYA shares. Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. UBS Group started coverage on IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Wedbush restated an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th.
Get Our Latest Stock Analysis on IDEAYA Biosciences
Institutional Investors Weigh In On IDEAYA Biosciences
IDEAYA Biosciences Stock Performance
IDYA opened at $24.85 on Friday. The firm has a market cap of $2.15 billion, a P/E ratio of -10.67 and a beta of 0.82. The business has a 50 day moving average price of $26.98 and a 200 day moving average price of $32.77. IDEAYA Biosciences has a twelve month low of $24.20 and a twelve month high of $47.74.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter last year, the firm earned ($0.46) earnings per share. As a group, analysts anticipate that IDEAYA Biosciences will post -2.45 earnings per share for the current fiscal year.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Featured Stories
- Five stocks we like better than IDEAYA Biosciences
- Investing In Automotive Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Using the MarketBeat Stock Split Calculator
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Why is the Ex-Dividend Date Significant to Investors?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.